<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01521793</url>
  </required_header>
  <id_info>
    <org_study_id>RET IRD 02</org_study_id>
    <nct_id>NCT01521793</nct_id>
  </id_info>
  <brief_title>Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)</brief_title>
  <official_title>An Open-Label Study to Evaluate the Effects of Repeated Treatments of Oral QLT091001 on Safety and Vision Outcome in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin: Retinol Acyltransferase (LRAT) (Extension of Study RET IRD 01)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QLT Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>QLT Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:&#xD;
&#xD;
        -  To evaluate the safety of up to 3 additional courses of oral QLT091001 administered once&#xD;
           daily for 7 days in subjects treated previously with a single 7-day course of QLT091001&#xD;
           in Study RET IRD 01&#xD;
&#xD;
        -  To evaluate whether up to 3 additional courses of oral QLT091001 administered once daily&#xD;
           for 7 days can maintain or improve visual function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual field</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be assessed by evaluating the following: adverse events, clinical laboratory tests, ECG's and vital signs</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">27</enrollment>
  <condition>LCA (Leber Congenital Amaurosis)</condition>
  <condition>RP (Retinitis Pigmentosa)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QLT091001</intervention_name>
    <description>oral QLT091001 administered once daily for 7 days</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with LCA or RP due to RPE65 or LRAT deficiency who received a 7-day treatment&#xD;
             course of QLT091001 and completed the Day 30 visit in Study RET IRD 01&#xD;
&#xD;
          -  Subjects who meet any one of the following criteria at least 1 month after start of&#xD;
             the 7-day treatment course in Study RET IRD 01:&#xD;
&#xD;
               -  no increase in GVF (in at least 1 eye): Follow-up GVF increased ≤20% from&#xD;
                  baseline or&#xD;
&#xD;
               -  decrease in GVF (in at least 1 eye): Follow-up GVF decreased below the highest&#xD;
                  previous response by ˃20% or&#xD;
&#xD;
               -  Considered a reasonable candidate for retreatment, based on the Investigator's&#xD;
                  discretion, in consultation with the independent DSMB and the Sponsor, based on&#xD;
                  regression or lack of response in other parameters of visual function (e.g.,&#xD;
                  subjective reports of changes in color vision or adaptation to low light) but who&#xD;
                  do not meet other (GVF) criteria for study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with any clinically important abnormal physical finding at Screening.&#xD;
&#xD;
          -  Subjects who have taken any prescription or investigational oral retinoid medication&#xD;
             (e.g., Accutane,® Soriatane®) within 6 months of Day 0 and subjects who did not&#xD;
             tolerate their previous oral retinoid medication will be excluded regardless of the&#xD;
             time of last exposure.&#xD;
&#xD;
          -  Subjects with liver failure, uncontrolled thyroid disease, hypersensitivity to&#xD;
             retinoids, or hypervitaminosis A&#xD;
&#xD;
          -  Subjects who have taken any supplements containing ≥10,000 IU vitamin A within 60 days&#xD;
             of screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sushanta Mallick</last_name>
    <role>Study Director</role>
    <affiliation>QLT Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Chicago Lighthouse (University of Illinois at Chicago, Pangere Center for Inherited Retinal Disease)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmer Eye Institute (Johns Hopkins University)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Children's Hospital, McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Ophthalmic Research, University of Tubingen</name>
      <address>
        <city>Tubingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Rotterdam Eye Hospital</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorefield Eye Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1 V2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>January 6, 2012</study_first_submitted>
  <study_first_submitted_qc>January 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2012</study_first_posted>
  <last_update_submitted>July 25, 2014</last_update_submitted>
  <last_update_submitted_qc>July 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blindness</mesh_term>
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Leber Congenital Amaurosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinol acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

